Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

CAMBRIDGE, Mass., Feb. 17 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2008. At December 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled $46.1 million.

Business Highlights

  • Idenix successfully completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had licensed its NNRTI program, including IDX899, to GlaxoSmithKline (GSK) and, subject to closing conditions, will receive a $34 million payment, $17 million of which will be a cash payment and the other $17 million representing the purchase of shares of Idenix common stock by GSK. Idenix will also be eligible to receive up to $416 million in development, regulatory and sales milestones.
  • During 2008, Idenix completed a phase I, healthy volunteer study of IDX184, its lead nucleotide polymerase inhibitor for the treatment of hepatitis C, and advanced the drug candidate into proof-of-concept testing in treatment-naive HCV-infected patients.
  • Additionally, during 2008, the company selected clinical candidates and continued IND-enabling preclinical studies for its lead HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs.

"Idenix began 2008 with a renewed focus on our discovery and development programs and ended the year with a successfully completed proof-of-concept study for IDX899 for the treatment o
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama signed ... Appropriations Act of 2015, which for the first time, ... the Congressionally Directed Medical Research Programs (CDMRP) administered by ... working in conjunction with its allies on Capitol Hill, ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... of the universities in the resund Region University ... together with MC2 at Chalmers University of Technology ... build up a network for co-operation within nanotechnology. , ... , Used efficiently, knowledge on nanotechnology will ...
... Required for Integra Merger, IRVINE, California, October 26 ... company, today announced that,it has adjourned its special meeting ... the acquisition of IsoTis by Integra,LifeSciences Holdings Corporation (NASDAQ: ... of merger dated as of August 6, 2007. ...
... Services,Inc. (NYSE: AHS ), the nation,s largest ... on Thursday, November 1, 2007 at 3.30 p.m.,Pacific ... place at the San,Diego Marriott Del Mar Hotel ... Susan R. Nowakowski, President and Chief Executive ...
Cached Biology Technology:IsoTis Adjourns Special Meeting to October 29, 2007 2IsoTis Adjourns Special Meeting to October 29, 2007 3IsoTis Adjourns Special Meeting to October 29, 2007 4AMN Healthcare Services to Present at the BIOCOM Investor Conference 2007 2
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics Agency is ... and prevent counterfeit microcircuits from entering into its supply ... in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The capability ... their reliability throughout the supply chain. The new quality ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... and skeletal deformities in people has been shown to ... adult mice, according to a recent study led by ... in early bone development, controls bone mineral density in ... Mutations in matrilin-3 have previously been linked to certain ...
... of Minnesota researchers have found a group of cells ... to turn on T-cells, cells that help fight infection. ... 2006 issue of the journal Immunity, released today. , ... response will help in studying and developing treatments for ...
... a specific cell protein can trigger the spread of cancer. ... of Edinburgh Cancer Research Centre could pave the way for ... normal cell cancerous. , The protein, MDM2, normally functions ... called p53. In some of the body's cells, the biochemical ...
Cached Biology News:Matrilin-3 gene discovered to prevent onset of osteoarthritis 2Matrilin-3 gene discovered to prevent onset of osteoarthritis 3
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
... Varian Cary 50 Microplate Reader ... cost per analysis by extending ... the award-winning Cary 50 instruments. ... to 384 samples in microlitre ...
... Polynucleotide Kinase for labeling of 5' ... acids. In the exchange reaction T4 ... group from DNA to ADP and ... to the free 5' hydroxyl group ...
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: